Zoryve foam (Roflumilast) is a topical treatment approved by the FDA for seborrheic dermatitis in people aged 9 and older. Here are some key points:

- Effectiveness: Clinical trials showed that after eight weeks, 80% of users achieved clear or almost clear skin, with significant improvements in symptoms like itch, redness Show Full Answer

Zoryve foam (Roflumilast) is a topical treatment approved by the FDA for seborrheic dermatitis in people aged 9 and older. Here are some key points:

- Effectiveness: Clinical trials showed that after eight weeks, 80% of users achieved clear or almost clear skin, with significant improvements in symptoms like itch, redness, and scaling. Some saw improvements as early as two days.
- Side Effects: Common side effects include nasopharyngitis, nausea, and headache. There are no listed rare but serious side effects.
- Usage: It is applied once daily to affected areas.
- Availability: Expected to be available to key wholesalers and dermatology pharmacy channels by the end of January.

For interactions with other medications, it's best to consult your dermatologist.

 This AI-generated response comes from MySebDermTeam and other selected sources. It is not a substitute for medical advice. Always ask your doctor about specific health concerns.

FDA Approves Zoryve Foam To Treat Seborrheic Dermatitis | MySebDermTeam

Zoryve Topical Foam (Roflumilast ) for Sebhorreic Dermatitis | MySebDermTeam